IXP Launches Maiden Rs 200 Cr Fund To Support Early- Stage Biotech Startups

IXP, a life sciences-focused VC firm backed by JV Ventures, has launched its first fund, IXP Lifesciences Catalyst Fund, to invest in early-stage biotech startups.

The fund has Rs 200 crore, with an extra Rs 100 crore as a greenshoe option, supporting startups from pre-seed to Series A.

It plans to invest in 20-25 companies across pharma, biotech, medtech, specialty chemicals, agrotech, and nutraceuticals.

Read also- Croft Beverages Secures $125K In Pre-Seed Round

The VC firm supports startups with funding, industry expertise, scientific guidance, and operational help.

“The sector requires investors with scientific expertise and industry knowledge. We have onboarded industry veterans as council members and advisors to support our portfolio companies,” said Ketki Tulpule, Chief Investment Officer at IXP.  

Jasmeet Chhabra, Partner at IXP and Co-founder of JV Ventures, said, “Early-stage companies need access to laboratories, networks, and R&D services, which we facilitate through PoweRx, the life sciences vertical of JV Ventures."

IXP Venture Studio collaborates with scientists to develop market-ready ideas, taking a hands-on approach from concept to scale. Its Venturepreneur Program helps scientists become founders.

To support early-stage startups, IXP provides access to labs, networks, and R&D services through PoweRx, the Life Sciences division of JV Ventures.

As an Innovation Acceleration Platform, IXP helps scientists and innovators navigate the capital-intensive and long R&D cycles of life sciences, ensuring their ideas reach the market.

IXP supports scientists and innovators by connecting them to a strong life sciences ecosystem. With a skilled team, it understands the high costs and long timelines of R&D and helps bring new ideas to market.

Startup Funding News: Your Gateway to Every Funding Update.

Latest Startup News: Stay updated with the latest startup news and trends. Your go-to source for startup ecosystem updates.